Managing patients on endocrine therapy: Focus on quality-of-life issues

Clinical Cancer Research

Volumn 12, Issue 3 II, 2006, Pages

  Whelan, Timothy J ^a   Pritchard, Kathleen I ^b   Arteaga, Carlos ^c   Come, Steven ^c   Ingle, James ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EXEMESTANE; GOSERELIN; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTHRALGIA; ARTHRITIS; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; FATIGUE; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HOT FLUSH; HUMAN; IRRITABILITY; MENOPAUSAL SYNDROME; MYALGIA; NAUSEA; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; VAGINA BLEEDING; VAGINA DISCHARGE; VASOMOTOR DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; OVARY; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 32944473164     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2185     Document Type: Conference Paper

References (18)

1. Guyatt GH, Jaeschke R. Measurements in clinical trials: choosing the appropriate approach Quality of life assessment in clinical trials. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press; 1990. p. 37-46.
2. Goodwin PJ, Black JT, Bordeleau L, Ganz PA. Health-related quality-of-life measurement in randomized clinical trials in breast cancer: taking stock. J Natl Cancer Inst 2003;95:263-81.
3. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term disease free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39-47.
4. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-40.
5. Love RR, Cameron L, Connell B. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-7.
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
7. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659-69.
8. Nystedt M, Berglund G, Bolund C. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer. Acta Oncol 2000;39:959-68.
9. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
10. Coombes RC, Hall E, Gibson L, et al. A randomized trial of exemestane after two to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N EnglJ Med 2004;350:1081-91.
11. The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003:98:1802-10.
12. Ingle JN. Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res 2006;12:1031-6s.
13. Fallowfield LJ, Price MH, Hall E, Coombes RC, Bliss JM. Intergroup Exemestane Study: results of the quality of life sub-protocol [abstract 4]. Br Cancer Res Treat 2004;88:S9.
14. Fallowfield L, Cella D, Cuzick J. Quality of life of postmenopausal women in the Arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:4261-71.
15. Cella D, Fallowfield L, on behalf of the ATAC Trialists Group. Five year quality of life follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), tamoxifen (T), alone or in combination (ATAC) Trial [abstract 577], J Clin Oncol 2005;23:16S.
16. Asmar L, Cantrell J, Vukelja S. A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study [abstract 516]. J Clin Oncol 2004;22:14S
17. Ganz PA, Moinpour CM, Pauler DK, et al. Health status and quality of life in patients with early-stage Hodgkins's disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 2003;21:3512-9.
18. Ganz PA, Greendale GA, Peterson LM, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054-64.